Prevalence of molecular markers of <it>Plasmodium falciparum</it> drug resistance in Dakar, Senegal
Wurtz Nathalie, Fall Bécaye, Pascual Aurélie and 13 more
Malaria Journal · 2012
doi:10.1186/1475-2875-11-197 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>As a result of the widespread resistance to chloroquine and sulphadoxine-pyrimethamine, artemisinin-based combination therapy (ACT) (including artemether-lumefantrine and artesunate-amodiaquine) has been recommended as a first-line anti-malarial regimen in Senegal since 2006. Intermittent preventive treatments with anti-malarial drugs based on sulphadoxine-pyrimethamine are also given to children or pregnant women once per month during the transmission season. Since 2006, there have been very few reports on the susceptibility of <it>Plasmodium falciparum</it> to anti-malarial drugs. To estimate the prevalence of resistance to several anti-malarial drugs since the introduction of the widespread use of ACT, the presence of molecular markers associated with resistance to chloroquine and sulphadoxine-pyrimethamine was assessed in local isolates at the military hospital of Dakar.</p> <p>Methods</p> <p>The prevalence of genetic polymorphisms in genes associated with anti-malarial drug resistance, i.e., <it>Pfcrt</it>, <it>Pfdhfr</it>, <it>Pfdhps</it> and <it>Pfmdr1</it>, and the copy number of <it>Pfmdr1</it> were evaluated for a panel of 174 isolates collected from patients recruited at the military hospital of Dakar from 14 October 2009 to 19 January 2010.</p> <p>Results</p> <p>The <it>Pfcrt</it> 76T mutation was identified in 37.2% of the samples. The <it>Pfmdr1</it> 86Y and 184F mutations were found in 16.6% and 67.6% of the tested samples, respectively. Twenty-eight of the 29 isolates with the 86Y mutation were also mutated at codon 184. Only one isolate (0.6%) had two copies of <it>Pfmdr1</it>. The <it>Pfdhfr</it> 108N/T, 51I and 59R mutations were identified in 82.4%, 83.5% and 74.1% of the samples, respectively. The double mutant (108N and 51I) was detected in 83.5% of the isolates, and the triple mutant (108N, 51I and 59R) was detected in 75.3%. The <it>Pfdhps</it> 437G, 436F/A and 613S mutations were found in 40.2%, 35.1% and 1.8% of the samples, respectively. There was no double mutant (437G and 540E) or no quintuple mutant (<it>Pfdhfr</it> 108N, 51I and 59R and <it>Pfdhps</it> 437G and 540E). The prevalence of the quadruple mutant (<it>Pfdhfr</it> 108N, 51I and 59R and <it>Pfdhps</it> 437G) was 36.5%.</p> <p>Conclusions</p> <p>Since 2004, the prevalence of chloroquine resistance had decreased. The prevalence of isolates with high-level pyrimethamine resistance is 83.5%. The prevalence of isolates resistant to sulphadoxine is 40.2%. However, no quintuple mutant (<it>Pfdhfr</it> 108N, 51I and 59R and <it>Pfdhps</it> 437G and 540E), which is associated with a high level of sulphadoxine-pyrimethamine resistance, has been identified to date. The resistance to amodiaquine remains moderate.</p>
Abstract licence: CC BY-NC-ND
Cited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.